Contrasting Bioventus (NASDAQ:BVS) & InspireMD (NYSE:NSPR)

InspireMD (NYSE:NSPR – Get Free Report) and Bioventus (NASDAQ:BVS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares InspireMD and Bioventus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InspireMD -413.96% -69.42% -57.68%
Bioventus 9.78% 26.31% 10.13%

Valuation and Earnings

This table compares InspireMD and Bioventus”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InspireMD $10.56 million 2.39 -$19.92 million ($0.59) -0.92
Bioventus $568.09 million 1.47 $22.73 million $0.80 12.35

Bioventus has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 25.0% of InspireMD shares are owned by insiders. Comparatively, 33.5% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for InspireMD and Bioventus, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InspireMD 0 0 3 0 3.00
Bioventus 0 1 5 0 2.83

InspireMD presently has a consensus target price of $4.50, suggesting a potential upside of 733.33%. Bioventus has a consensus target price of $16.60, suggesting a potential upside of 68.02%. Given InspireMD’s stronger consensus rating and higher possible upside, research analysts clearly believe InspireMD is more favorable than Bioventus.

Volatility and Risk

InspireMD has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Summary

Bioventus beats InspireMD on 10 of the 14 factors compared between the two stocks.

About InspireMD

(Get Free Report)

InspireMD is a medical technology company focused on developing devices for the treatment of carotid artery disease, a condition that can increase the risk of stroke. The company’s technology is designed to help protect against debris traveling to the brain during procedures to open narrowed arteries. Its lead product is the CGuard carotid stent system, which combines a metal stent with a fine mesh covering called MicroNet. The mesh is designed to help trap plaque and other material while allowing blood to flow through the artery.

About Bioventus

(Get Free Report)

Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.